BriaCell Therapeutics Statistics
Want to see TSE:BCT full AI Analyst Report?
BriaCell Therapeutics (BCT) Stock Statistics & Valuation Metrics
Total Valuation
BriaCell Therapeutics has a market cap or net worth of CAD 44.36M. The enterprise value is CAD 11.98M.
- Market Cap
- CAD 44.36M
- Enterprise Value
- CAD 11.98M
Share Statistics
BriaCell Therapeutics has 8,732,381 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 8,732,381
- Owned by Insiders
- 32.28%
- Owned by Institutions
- 0.78%
Financial Efficiency
BriaCell Therapeutics’s return on equity (ROE) is -2.16 and return on invested capital (ROIC) is -234.64%.
- Return on Equity (ROE)
- -2.16
- Return on Assets (ROA)
- -1.50
- Return on Invested Capital (ROIC)
- -234.64%
- Return on Capital Employed (ROCE)
- -2.35
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.14M
- Employee Count
- 31
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BriaCell Therapeutics is -0.37. BriaCell Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.37
- PS Ratio
- 0.00
- PB Ratio
- 1.83
- Price to FCF
- -1.05
- Price to Operating Cash Flow
- -1.05
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, BriaCell Therapeutics had revenue of 0 and earned -35.42M in profits. Earnings per share was -7.07.
- Revenue
- 0
- Gross Profit
- -121.09K
- Operating Income
- -36.58M
- Pretax Income
- -35.84M
- Net Income
- -35.42M
- EBITDA
- -36.46M
- Earnings Per Share (EPS)
- -7.07
Cash Flow
In the last 12 months, operating cash flow was -28.57M and capital expenditures -128,410, giving a free cash flow of -28.70M billion.
- Operating Cash Flow
- -28.57M
- Free Cash Flow
- -28.70M
- Free Cash Flow per Share
- -3.30
Dividends & Yields
BriaCell Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -95.61%
- Earnings Yield
- -115.97%
Stock Price Statistics
- Beta
- 1.69
- 52-Week Price Change
- -65.25%
- 50-Day Moving Average
- 5.23
- 200-Day Moving Average
- 5.21
- Relative Strength Index (RSI)
- 51.31
- Average Volume (3m)
- 7,288
Important Dates
BriaCell Therapeutics upcoming earnings date is Dec 10, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Dec 10, 2026
- Ex-Dividend Date
- ―
Financial Position
BriaCell Therapeutics as a current ratio of 2.76, with Debt / Equity ratio of 0.00%
- Current Ratio
- 2.76
- Quick Ratio
- 2.76
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.27
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, BriaCell Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
BriaCell Therapeutics EV to EBITDA ratio is -0.57, with an EV/FCF ratio of -0.70.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.57
- EV to Free Cash Flow
- -0.70
- EV to Operating Cash Flow
- -0.71
Balance Sheet
BriaCell Therapeutics has CAD 20.53M in cash and marketable securities with CAD 0.00 in debt, giving a net cash position of CAD 20.53M billion.
- Cash & Marketable Securities
- CAD 20.53M
- Total Debt
- CAD 0.00
- Net Cash
- CAD 20.53M
- Net Cash Per Share
- CAD 2.35
- Tangible Book Value Per Share
- CAD 1.77
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for BriaCell Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 87.90%
Scores
- Smart Score
- 1
- AI Score
- 45
